about
Simultaneously Targeting the NS3 Protease and Helicase Activities for More Effective Hepatitis C Virus TherapyHepatitis C virus subgenomic replicon requires an active NS3 RNA helicase.Hepatitis C Virus NS3 ATPases/Helicases from Different Genotypes Exhibit Variations in Enzymatic PropertiesRole of Divalent Metal Cations in ATP Hydrolysis Catalyzed by the Hepatitis C Virus NS3 Helicase: Magnesium Provides a Bridge for ATP to Fuel UnwindingAnalysis of the Evolutionary Forces in an Immunodominant CD8 Epitope in Hepatitis C Virus at a Population LevelEffects of Mutagenic and Chain-Terminating Nucleotide Analogs on Enzymes Isolated from Hepatitis C Virus Strains of Various GenotypesMonitoring helicase activity with molecular beaconsCyclophilin B stimulates RNA synthesis by the HCV RNA dependent RNA polymeraseFuel Specificity of the Hepatitis C Virus NS3 HelicaseHelicase inhibitors as specifically targeted antiviral therapy for hepatitis CMechanism and Specificity of a Symmetrical Benzimidazolephenylcarboxamide Helicase InhibitorA Method to Simultaneously Monitor Hepatitis C Virus NS3 Helicase and Protease ActivitiesSolution structure of the MutT enzyme, a nucleoside triphosphate pyrophosphohydrolaseStudies on the ADP-ribose pyrophosphatase subfamily of the nudix hydrolases and tentative identification of trgB, a gene associated with tellurite resistance.DNA damage alters DNA polymerase delta to a form that exhibits increased discrimination against modified template bases and mismatched primersThe MutT proteins or "Nudix" hydrolases, a family of versatile, widely distributed, "housecleaning" enzymesThe p12 subunit of human polymerase delta modulates the rate and fidelity of DNA synthesis.Ceestatin, a novel small molecule inhibitor of hepatitis C virus replication, inhibits 3-hydroxy-3-methylglutaryl-coenzyme A synthase.PSI-7851, a pronucleotide of beta-D-2'-deoxy-2'-fluoro-2'-C-methyluridine monophosphate, is a potent and pan-genotype inhibitor of hepatitis C virus replicationIvermectin is a potent inhibitor of flavivirus replication specifically targeting NS3 helicase activity: new prospects for an old drug.Identification and analysis of hepatitis C virus NS3 helicase inhibitors using nucleic acid binding assaysEbselen inhibits hepatitis C virus NS3 helicase binding to nucleic acid and prevents viral replicationPrimuline derivatives that mimic RNA to stimulate hepatitis C virus NS3 helicase-catalyzed ATP hydrolysis.Aurintricarboxylic acid modulates the affinity of hepatitis C virus NS3 helicase for both nucleic acid and ATPHelicases as antiviral drug targets.Discovering new medicines targeting helicases: challenges and recent progress.Benzothiazole and Pyrrolone Flavivirus Inhibitors Targeting the Viral Helicase.Analysis of the Enzymatic Activity of an NS3 Helicase Genotype 3a Variant Sequence Obtained from a Relapse Patient.Computer-aided identification, synthesis and evaluation of substituted thienopyrimidines as novel inhibitors of HCV replication.Shape-based virtual screening, synthesis and evaluation of novel pyrrolone derivatives as antiviral agents against HCV.Optimization of potent hepatitis C virus NS3 helicase inhibitors isolated from the yellow dyes thioflavine S and primuline.Understanding helicases as a means of virus control.Step-by-step progress toward understanding the hepatitis C virus RNA helicase.Identification and analysis of inhibitors targeting the hepatitis C virus NS3 helicaseThe nonstructural protein 3 protease/helicase requires an intact protease domain to unwind duplex RNA efficientlyFluorescent primuline derivatives inhibit hepatitis C virus NS3-catalyzed RNA unwinding, peptide hydrolysis and viral replicase formation.Two novel conserved motifs in the hepatitis C virus NS3 protein critical for helicase action.Enhanced nucleic acid binding to ATP-bound hepatitis C virus NS3 helicase at low pH activates RNA unwinding.Electrostatic analysis of the hepatitis C virus NS3 helicase reveals both active and allosteric site locations.Development of novel therapies for hepatitis C.
P50
Q26700073-8B8E17D4-81A7-49F7-BF16-415180DD57D6Q27472781-BA410EF8-7C0F-45D4-AD26-DED2B94FE43DQ27473372-A7C1E94E-CDBA-4F0E-8514-70754EECA8AEQ27478187-35ABB76A-A8B6-48A7-9DB1-DF0E92ED3DA8Q27485493-02DF8EDD-1718-447E-A4A0-5B854576A6E7Q27486248-9AA28CB3-CCE1-4112-AEFC-977A7E750687Q27487294-2D5583CD-542D-4BDB-8ACA-F7CE54FD9003Q27488216-5AEFA6B3-3F64-4368-9229-C034F3BAB2BAQ27488702-6F24C944-67AB-4F87-9052-3198E1408FC0Q27488958-4445A47E-CB69-482A-9A10-832F7968B4B8Q27491015-A7818E7F-F68B-403C-9FF4-57DD48CB79B7Q27491152-AB89341E-1CE5-42D2-8E19-28C5DAC1840AQ27729722-FE01243A-B1DD-455C-BAE3-691C0859BD4DQ27934562-FEEFE568-FC57-4282-9EA2-701A3CA289B6Q28303644-0387C44D-0596-40D4-A205-189E315B8E80Q28573848-E4B68075-F8C3-4E9B-BF61-8FD1D549B5D6Q33814597-EBBD5B7F-D00D-4CF2-BEB2-3010051B75EFQ33972367-3614EB14-DB66-46C4-A271-DDD3EBE35961Q34045444-32335EB4-6938-4B00-9681-9F20B565D46CQ34246661-D909290B-3067-4F98-9FA2-1E7D8A76C45FQ34319607-9B626EEE-5DF0-440F-ABA3-6C33DF2371E4Q34361091-7303CF4C-EA60-418F-90BD-2A9CBA818B5BQ34736874-A7ABA891-0CC2-45F4-BFC6-F8C49AA7BB13Q34744743-B0EAFFAE-62D0-44E0-A1D6-99E0EDF87848Q35218580-052CC84B-1C60-4FFE-BBFA-1FB58BC36643Q35592783-592CB8CF-8BA1-4CAC-937E-84679554D144Q35647755-B3160D88-8314-4E3D-91FD-43630C59BDA0Q35866961-2C19869F-22A8-43ED-A840-E84CE2BEC5D1Q36090693-D7CE5054-5157-417B-AD10-B0FD12082DEBQ36250097-8E185494-E565-43E5-8935-4A9313A654C6Q36334762-AAF97948-0ADA-4649-8187-D4F7917176E2Q36447325-3320FA03-4443-4E57-83AD-6C578FEB27E1Q36490245-1C8D9E77-CDC6-4F72-A99B-B37EE330063EQ36607790-C2339DFC-B752-4549-9E7F-EDF76EDCED33Q36607807-99824D28-437F-451D-8E69-2CBB4844B67BQ36607822-0EE4B8EB-2F32-4D67-8B50-503CED5665C6Q36607832-61E3D97C-9CD6-43E5-B666-AB9F78172202Q37346577-1B89CBC5-6727-4923-A382-1A1E823F443BQ37592346-1DDE5EFD-58DC-42BB-AC3B-04BC5D5A85DFQ37736815-3B53A841-64B5-4595-9535-B9D69F927A33
P50
description
researcher
@en
wetenschapper
@nl
հետազոտող
@hy
name
David N. Frick
@ast
David N. Frick
@en
David N. Frick
@es
David N. Frick
@nl
David N. Frick
@sl
type
label
David N. Frick
@ast
David N. Frick
@en
David N. Frick
@es
David N. Frick
@nl
David N. Frick
@sl
prefLabel
David N. Frick
@ast
David N. Frick
@en
David N. Frick
@es
David N. Frick
@nl
David N. Frick
@sl
P106
P1153
7003968341
P21
P31
P496
0000-0002-2434-7223